Share on StockTwits

Cellectar Biosciences (NASDAQ:CLRB) CEO Simon Pedder purchased 13,300 shares of Cellectar Biosciences stock on the open market in a transaction dated Wednesday, August 20th. The stock was purchased at an average price of $3.75 per share, with a total value of $49,875.00. Following the completion of the purchase, the chief executive officer now directly owns 13,300 shares in the company, valued at approximately $49,875. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Cellectar Biosciences (NASDAQ:CLRB) traded up 1.60% during mid-day trading on Friday, hitting $3.05. 29,020 shares of the company’s stock traded hands. Cellectar Biosciences has a 52 week low of $3.00 and a 52 week high of $9.20. The stock’s 50-day moving average is $5.67 and its 200-day moving average is $7.06. The company’s market cap is $8.8 million.

Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc is engaged in developing agents to detect, treat and monitor a broad spectrum of cancers.

Receive News & Ratings for Cellectar Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.